Sigyn Therapeutics, Inc. (OTCQB: SIGY), developer of the CardioDialysis blood purification device, announced a new initiative to evaluate emerging medical technologies in former NFL players at risk of chronic traumatic encephalopathy (CTE). The initiative focuses on addressing the role of chronic inflammation in driving CTE progression, following recent research from Trinity College Dublin that found the blood-brain barrier can remain compromised for decades after retirement from collision sports.
Former NFL players face significantly higher rates of neurodegenerative diseases, including ALS, Parkinson’s disease, and CTE. Post-mortem studies have diagnosed CTE in a majority of former players. While repetitive head trauma initiates CTE, chronic inflammation is now understood to be the principal driver of disease progression. The Trinity College study revealed that a compromised blood-brain barrier allows inflammatory and pathogenic molecules to leak into the brain, triggering neuroinflammation that accelerates abnormal tau-protein accumulation—the hallmark of CTE.
Sigyn’s initiative plans to evaluate the feasibility of CardioDialysis, an extracorporeal blood purification technology designed to reduce circulating inflammatory and pathogenic molecules known to fuel CTE progression. CardioDialysis integrates plasma separation and therapeutic adsorption into a single device, enabling continuous broad-spectrum clearance of targets including inflammatory cytokines TNF-alpha, IL-1 beta, IL-6, and bacterial endotoxin—key blood-brain barrier-crossing contributors to CTE. The initiative will also assess blood-based neuron-derived exosome assays for monitoring CTE progression and response to therapies, as well as other candidate therapies such as a tau vaccine and a brain-delivered anti-inflammatory drug agent.
Jim Joyce, CEO of Sigyn Therapeutics, stated: “Based on my previous participation in two landmark studies of CTE in former NFL players, the knowledge that the brains of collision sport athletes can remain permeable for decades opens the door to new strategies to diagnose CTE in the living and for treating the disease through a targeted control of inflammation.”
CardioDialysis is positioned within the emerging field of subtractive medicine, aiming to address conditions driven by systemic inflammation, including sepsis, life-threatening viral infections, neuroinflammatory disorders, and cardiovascular disease. For cardiovascular disease, the device targets inflammatory mediators and cholesterol-transporting lipoproteins. The company’s pipeline also includes ImmunePrep, ChemoPrep, and ChemoPure technologies for cancer therapy.
For more information, visit www.SigynTherapeutics.com.
